DE69333287D1 - Neuartige glykoformen als lösliche komplement-rezeptoren - Google Patents

Neuartige glykoformen als lösliche komplement-rezeptoren

Info

Publication number
DE69333287D1
DE69333287D1 DE69333287T DE69333287T DE69333287D1 DE 69333287 D1 DE69333287 D1 DE 69333287D1 DE 69333287 T DE69333287 T DE 69333287T DE 69333287 T DE69333287 T DE 69333287T DE 69333287 D1 DE69333287 D1 DE 69333287D1
Authority
DE
Germany
Prior art keywords
glycoforms
scr1
innovative
soluble complement
complement receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69333287T
Other languages
English (en)
Other versions
DE69333287T2 (de
Inventor
C Marsh
Richard A G Smith
Chang-Jing Grace Yeh
John Lifter
Anne Mary Freeman
L Gosselin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celldex Therapeutics Inc
Original Assignee
Avant Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avant Immunotherapeutics Inc filed Critical Avant Immunotherapeutics Inc
Publication of DE69333287D1 publication Critical patent/DE69333287D1/de
Application granted granted Critical
Publication of DE69333287T2 publication Critical patent/DE69333287T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DE69333287T 1992-08-07 1993-08-06 Neuartige glykoformen als lösliche komplement-rezeptoren Expired - Lifetime DE69333287T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/927,099 US5456909A (en) 1992-08-07 1992-08-07 Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US927099 1992-08-07
PCT/US1993/007406 WO1994003603A1 (en) 1992-08-07 1993-08-06 Novel glycoforms of soluble complement receptor 1

Publications (2)

Publication Number Publication Date
DE69333287D1 true DE69333287D1 (de) 2003-12-11
DE69333287T2 DE69333287T2 (de) 2004-09-23

Family

ID=25454172

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69333287T Expired - Lifetime DE69333287T2 (de) 1992-08-07 1993-08-06 Neuartige glykoformen als lösliche komplement-rezeptoren

Country Status (15)

Country Link
US (3) US5456909A (de)
EP (1) EP0656061B1 (de)
JP (1) JP3662250B2 (de)
CN (1) CN1089951A (de)
AT (1) ATE253591T1 (de)
CA (1) CA2141842C (de)
DE (1) DE69333287T2 (de)
DK (1) DK0656061T3 (de)
ES (1) ES2210241T3 (de)
IL (1) IL106558A (de)
MX (1) MX9304800A (de)
PT (1) PT656061E (de)
TW (1) TW386878B (de)
WO (1) WO1994003603A1 (de)
ZA (1) ZA935728B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
CA2162600C (en) * 1993-05-17 2000-07-11 Chrales W. Rittershaus Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
DE69534701T2 (de) 1994-09-23 2006-10-19 Alexion Pharmaceuticals, Inc., Cheshire Verfahren zur behandlung von entzündlichen gelenkerkrankungen
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US7112327B2 (en) * 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
KR100425965B1 (ko) * 1998-02-20 2004-04-06 타녹스 인코퍼레이티드 보체 활성화의 억제물질
SE0004808D0 (sv) * 2000-12-20 2000-12-20 Apbiotech Ab Method for the purification of an enzyme
US20040214228A9 (en) * 2001-09-14 2004-10-28 Ganesh Venkataraman Methods of evaluating glycomolecules for enhanced activities
EP1438387A4 (de) * 2001-09-14 2004-10-13 Momenta Pharmaceuticals Inc Verfahren zur herstellung von glycomolekülen mit verstärkten aktivitäten und verwendungen davon
WO2004094823A2 (en) 2003-04-23 2004-11-04 Biovalve Technologies, Inc. Hydraulically actuated pump for long duration medicament administration
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
JP4507682B2 (ja) * 2004-04-26 2010-07-21 三菱化学株式会社 糖鎖分離方法、検体分析方法、液体クロマトグラフィー装置、並びに糖鎖分析方法及び糖鎖分析装置
US20090028850A1 (en) * 2004-05-14 2009-01-29 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
EP1738763A1 (de) 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Verwendung eines Komplement-inhibierenden Proteins zur Behandlung von Rückenmarksverletzungen
US20070004625A1 (en) * 2005-06-30 2007-01-04 Li Liang-Man Use of complement inhibitory proteins to treat spinal cord injury
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
CA2624393C (en) * 2005-11-04 2016-01-05 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
EP1969007B1 (de) 2005-12-20 2013-08-28 Bristol-Myers Squibb Company Zusammensetzungen und verfahren zur herstellung einer zusammensetzung
WO2007103134A2 (en) * 2006-03-02 2007-09-13 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
HUE026496T2 (en) * 2006-03-08 2016-06-28 Archemix Llc Complement-binding aptamers and anti-C5 agents for treating eye diseases
AU2007225044C1 (en) 2006-03-15 2018-03-29 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
US7914499B2 (en) 2006-03-30 2011-03-29 Valeritas, Inc. Multi-cartridge fluid delivery device
EP2913342A1 (de) 2006-09-05 2015-09-02 Alexion Pharmaceuticals, Inc. Zusammensetzungen zur behandlung von antikörpervermittelten neuropathien
CA2666843C (en) * 2006-10-20 2015-06-16 Celldex Therapeutics, Inc. Treatment of age-related macular degeneration and other diseases of the eye
MY157948A (en) * 2006-11-02 2016-08-30 Genentech Inc Humanized anti-factor d antibodies
LT3597659T (lt) 2007-07-09 2023-05-10 Genentech, Inc. Disulfidinės jungties redukcijos prevencijos būdas gaminant polipeptidą rekombinantiniu būdu
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
KR20120027055A (ko) * 2009-06-26 2012-03-20 리제네론 파라마큐티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
BR112012025645A2 (pt) 2010-04-07 2017-12-12 Momenta Pharmaceuticals Inc glicanos de alta manose.
CN107661491A (zh) * 2010-09-15 2018-02-06 赛尔戴克斯治疗公司 用可溶性I型补体受体(sCR1)治疗慢性肾病
US9649356B2 (en) 2010-10-27 2017-05-16 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type I (sCR1)
EP2686671A4 (de) 2011-03-12 2015-06-24 Momenta Pharmaceuticals Inc N-acetylhexosamin-haltige n-glykane in glycoproteinprodukten
WO2013013193A1 (en) * 2011-07-20 2013-01-24 Zepteon, Incorporated Polypeptide separation methods
EP2856159A4 (de) 2012-06-01 2016-04-13 Momenta Pharmaceuticals Inc Verfahren im zusammenhang mit denosumab
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
US20160257754A1 (en) 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
CA2944712A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
US20210238238A1 (en) * 2018-05-16 2021-08-05 Csl Limited Soluble complement receptor type i variants and uses thereof
EP3581203A1 (de) * 2018-06-11 2019-12-18 Laboratoire Français du Fractionnement et des Biotechnologies Antikörper mit erhöhter aktivität im verdauungstrakt
WO2023240322A1 (en) * 2022-06-17 2023-12-21 CSL Innovation Pty Ltd Purification of soluble complement receptor and variants thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) * 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
IL89790A (en) * 1988-04-01 2002-05-23 Johns Hopking University Sequences of nucleic acids encoding and cells producing CR1 protein and methods for its production and purification
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
WO1992010205A1 (en) * 1990-12-06 1992-06-25 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo

Also Published As

Publication number Publication date
US5858969A (en) 1999-01-12
IL106558A0 (en) 1993-12-08
WO1994003603A1 (en) 1994-02-17
AU670453B2 (en) 1996-07-18
CN1089951A (zh) 1994-07-27
CA2141842C (en) 2008-07-29
EP0656061B1 (de) 2003-11-05
ZA935728B (en) 1994-03-03
DK0656061T3 (da) 2004-03-15
JP3662250B2 (ja) 2005-06-22
ES2210241T3 (es) 2004-07-01
US6057131A (en) 2000-05-02
MX9304800A (es) 1994-05-31
EP0656061A1 (de) 1995-06-07
IL106558A (en) 1998-10-30
DE69333287T2 (de) 2004-09-23
PT656061E (pt) 2004-03-31
US5456909A (en) 1995-10-10
JPH08501773A (ja) 1996-02-27
ATE253591T1 (de) 2003-11-15
TW386878B (en) 2000-04-11
AU4804193A (en) 1994-03-03
CA2141842A1 (en) 1994-02-17

Similar Documents

Publication Publication Date Title
DE69333287D1 (de) Neuartige glykoformen als lösliche komplement-rezeptoren
HUT63063A (en) Process for producing antibodies against cd44 cell surface glycoprotein and immunosuppressant pharmaceutical compositions comprising same
GR3007096T3 (de)
KR100206481B1 (en) Galenic form for ocular administration and process for the preparation of same
MY111196A (en) Therapeutic aplication of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
MY109143A (en) Sulfonamido-and sulfonamidocarbonylpyridine 2-carboxamides and their pyridine-n-oxides, process for their preparation and their use as pharmaceuticals
EP0154344A3 (en) Antiviral pharmaceutical preparations and methods for their use
AU6989094A (en) Compositions and methods for treating cancer and hyperproliferative disorders
AU7690596A (en) Anti-CD6 monoclonal antibodies and their uses
ITMI922331A0 (it) Uso di paratormone suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto protermine ed in generale per il trattamento della gestazione
GR3006815T3 (de)
CA2094347A1 (en) A method of producing a factor viii preparation
IT9067434A0 (it) Procedimento per migliorare l'efficacia terapeutica di corticosteroidi liposolubili e composizione per l'attuazione di tale procedimento
CA2062047A1 (en) Fusion proteins for prodrug activation, the preparation and use thereof
EP0336368A3 (en) N2-(1-carboxy-3-phenylpropyl)-l-lysine derivative and process of producing lysinopril using the compound
AU2456888A (en) Monoclonal antibodies specific for HIV and hybridomas for their production
EP1199361A3 (de) Glycoprotein HormonRezeptor Moleküle. Ihre Verwendungen
EP0478689A4 (en) Human monoclonal antibodies to hiv-1 mn? gp 120
IT9020020A0 (it) "n,n'-ditrimetossibenzoilpiperazine 2-sostituite, procedimento per la loro preparazione e composizioni terapeutiche che le contengono
AU4959193A (en) High affinity, strongly neutralizing monoclonal antibodies against the CD-4 binding site of GP120 of human immunodeficiency virus
IE840977L (en) Pharmaceutical preparations
IT8921513A0 (it) Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmacuetiche che li contengono.
AU680836B2 (en) Human monoclonal antibodies to human immunodeficiency virus
TW372873B (en) A novel anti-neoplastic cytokine

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CELLDEX THERAPEUTICS,INC. (N. D. GES.D.STAATES, US